153 related articles for article (PubMed ID: 35397434)
1. Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors.
Ochsenreither S; Fiedler WM; Conte GD; Macchini M; Matos I; Habel B; Ahrens-Fath I; Raspagliesi F; Lorusso D; Keilholz U; Rolling C; Kebenko M; Klinghammer KF; Saavedra O; Baumeister H; Zurlo A; Garralda E
ESMO Open; 2022 Apr; 7(2):100447. PubMed ID: 35397434
[TBL] [Abstract][Full Text] [Related]
2. Erratum to 'Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors': [ESMO Open Volume 7, Issue 2, April 2022, 100447].
Ochsenreither S; Fiedler WM; Del Conte G; Macchini M; Matos I; Habel B; Ahrens-Fath I; Raspagliesi F; Lorusso D; Keilholz U; Rolling C; Kebenko M; Klinghammer KF; Saavedra O; Baumeister H; Zurlo A; Garralda A
ESMO Open; 2022 Aug; 7(4):100549. PubMed ID: 35841804
[No Abstract] [Full Text] [Related]
3. Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study.
Ledermann JA; Zurawski B; Raspagliesi F; De Giorgi U; Arranz Arija J; Romeo Marin M; Lisyanskaya A; Póka RL; Markowska J; Cebotaru C; Casado Herraez A; Colombo N; Kutarska E; Hall M; Jacobs A; Ahrens-Fath I; Baumeister H; Zurlo A; Sehouli J
ESMO Open; 2022 Feb; 7(1):100311. PubMed ID: 34920291
[TBL] [Abstract][Full Text] [Related]
4. Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer.
Heublein S; Page S; Mayr D; Schmoeckel E; Trillsch F; Marmé F; Mahner S; Jeschke U; Vattai A
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30642093
[TBL] [Abstract][Full Text] [Related]
5. TA-MUC1 as detected by the fully humanized, therapeutic antibody Gatipotzumab predicts poor prognosis in cervical cancer.
Heublein S; Friese K; Kost B; Marmé F; Kuhn C; Mahner S; Dannecker C; Mayr D; Jeschke U; Vattai A
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1899-1907. PubMed ID: 30062487
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas.
Fiedler W; DeDosso S; Cresta S; Weidmann J; Tessari A; Salzberg M; Dietrich B; Baumeister H; Goletz S; Gianni L; Sessa C
Eur J Cancer; 2016 Aug; 63():55-63. PubMed ID: 27285281
[TBL] [Abstract][Full Text] [Related]
7. Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
Reck M; Garon EB; Paz-Ares L; Ponce S; Jaime JC; Juan O; Nadal E; Kiura K; Widau RC; He S; Dalal R; Lee P; Nakagawa K
Clin Lung Cancer; 2018 May; 19(3):213-220.e4. PubMed ID: 29317191
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC).
Kollmannsberger C; Schittenhelm M; Honecker F; Tillner J; Weber D; Oechsle K; Kanz L; Bokemeyer C
Ann Oncol; 2006 Jun; 17(6):1007-13. PubMed ID: 16533873
[TBL] [Abstract][Full Text] [Related]
9. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck - the RESGEX study.
Klinghammer K; Fayette J; Kawecki A; Dietz A; Schafhausen P; Folprecht G; Rottey S; Debourdeau P; Lavernia J; Jacobs A; Ahrens-Fath I; Dietrich B; Baumeister H; Zurlo A; Ochsenreither S; Keilholz U
ESMO Open; 2021 Oct; 6(5):100242. PubMed ID: 34482179
[TBL] [Abstract][Full Text] [Related]
11. A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors.
Oh DY; Lee KW; Han SW; Kim JW; Shin JW; Jo SJ; Won J; Hahn S; Lee H; Kim WH; Bang YJ
Oncologist; 2019 Aug; 24(8):1037-e636. PubMed ID: 31164456
[TBL] [Abstract][Full Text] [Related]
12. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
Gulley JL; Rajan A; Spigel DR; Iannotti N; Chandler J; Wong DJL; Leach J; Edenfield WJ; Wang D; Grote HJ; Heydebreck AV; Chin K; Cuillerot JM; Kelly K
Lancet Oncol; 2017 May; 18(5):599-610. PubMed ID: 28373005
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors.
Ma Y; Xue J; Zhao Y; Zhang Y; Huang Y; Yang Y; Fang W; Guo Y; Li Q; Ge X; Sun J; Zhang B; Zhang Y; Xiao J; Zhang L; Zhao H
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37263673
[TBL] [Abstract][Full Text] [Related]
14. A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment.
Delord JP; Argilés G; Fayette J; Wirth L; Kasper S; Siena S; Mesia R; Berardi R; Cervantes A; Dekervel J; Zhao S; Sun Y; Hao HX; Tiedt R; Vicente S; Myers A; Siu LL
Invest New Drugs; 2020 Dec; 38(6):1774-1783. PubMed ID: 32410080
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial.
Qiu MZ; Zhang Y; Guo Y; Guo W; Nian W; Liao W; Xu Z; Zhang W; Zhao HY; Wei X; Xue L; Tang W; Wu Y; Ren G; Wang L; Xi J; Jin Y; Li H; Hu C; Xu RH
JAMA Oncol; 2022 Jul; 8(7):1042-1046. PubMed ID: 35511148
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas.
Fiedler W; Cresta S; Schulze-Bergkamen H; De Dosso S; Weidmann J; Tessari A; Baumeister H; Danielczyk A; Dietrich B; Goletz S; Zurlo A; Salzberg M; Sessa C; Gianni L
ESMO Open; 2018; 3(2):e000303. PubMed ID: 29464112
[TBL] [Abstract][Full Text] [Related]
17. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
18. First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.
Cole CB; Morelli MP; Fantini M; Miettinen M; Fetsch P; Peer C; Figg WD; Yin T; Houston N; McCoy A; Lipkowitz S; Zimmer A; Lee JM; Pavelova M; Villanueva EN; Trewhitt K; Solarz BB; Fergusson M; Mavroukakis SA; Zaki A; Tsang KY; Arlen PM; Annunziata CM
J Exp Clin Cancer Res; 2023 Mar; 42(1):76. PubMed ID: 36991390
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
20. Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer.
Pegram MD; Borges VF; Ibrahim N; Fuloria J; Shapiro C; Perez S; Wang K; Schaedli Stark F; Courtenay Luck N
Breast Cancer Res; 2009; 11(5):R73. PubMed ID: 19811637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
